Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer

摘要: The treatment of cancer is continually improving as a result better understanding oncogenesis and the development new targeted compounds. Early clinical trials evaluating such candidate compounds require large number patients, are expensive, time consuming, expose patients to certain risks. To select most effective molecules, preclinical investigation antitumor an important step in drug process. Three main categories models generally used investigations, namely genetically engineered models, xenografts derived from human tumor cell lines, fragments implanted directly into immunodeficient mice, known tumorgrafts. establishment tumorgrafts constitutes long-term process consisting various steps, which final objective show that validated model accurately reproduces cancer, with high predictive value therapeutic efficacy (regardless type treatment), closely mimics situations frequently observed resistance standard treatments, metastases, relapse after initial therapies (involving residual tumor-initiating cells). aim this study therefore discuss proposed criteria for validation cancers should be further pharmacological assessments.